Trial Profile
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 2b Dose-finding Study to Investigate the Efficacy and Safety of Ligelizumab (QGE031) in Adolescent Patients With Chronic Spontaneous Urticaria (CSU)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Aug 2023
Price :
$35
*
At a glance
- Drugs Ligelizumab (Primary)
- Indications Chronic urticaria
- Focus Therapeutic Use
- Sponsors Novartis; Novartis Healthcare; Novartis Pharmaceuticals
- 01 Jul 2023 Results published in the Pediatric Allergy and Immunology
- 28 Feb 2022 First Results from phase IIB, presented at the 2022 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
- 27 Apr 2021 Status changed from active, no longer recruiting to completed.